linjc16/ctgov huggingface dataset:
iTBS Can Increase Frontal Dopamine Release in PET Dopamine Imaging.

Study Overview
=================
Brief Summary
-----------------
Aim: 1. To confirm that patients with predominant negative symptoms in schizophrenia have deficits in frontal cortical dopamine release when compared with healthy control and patients with positive symptoms. 2. Our previous study found patients with negative symptoms have more possibilities to have disorders in glucose metabolism, we wonder whether dopamine release, negative symptoms or glucose metabolism can be improved by iTBS. Study design: Case control study.

Detailed Description
-----------------
Eligibility Criteria: Predominant negative symptoms for Positive and Negative Syndrome Scale factor score for negative symptoms of 24 or more, and score of 4 or more on at least two of three core negative PANSS items, PANSS for positive symptoms of 19 or less, HAMD depression scale of 16 or less. Predominant positive symptoms for PANSS for positive symptoms of 20 or more. Healthy control will be recruited matching the age and sex of patient groups, Outcome Measures: Oral glucose tolerance test (OGTT), PET dopamine imaging.

Official Title
-----------------
iTBS Can Increase Frontal Dopamine Release and Improve Glucose Metabolism in PET Dopamine Imaging of Patients With Schizophrenia.

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Device: Theta burst stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for negative group diagnosed with schizophrenia according to ICD-10 or DSM-V Positive and Negative Syndrome Scale factor score for negative symptoms of 24 or moreand score of 4 or more on at least two of three core negative PANSS items PANSS for positive symptoms of 19 or less, and HAMD depression scale of 16 or less. drug-naive Inclusion Criteria for positive group PANSS for positive symptoms of 20 or more drug-naive Exclusion Criteria: drug or alcohol addiction diagnosed with other major mental disorders according to ICD-10 or DSM-V

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: predominant negative symptoms<br>iTBS for predominant negative symptoms | Device: Theta burst stimulation<br>* a new paradigm of high frequency repetitive transcranial magnetic stimulation<br>|
| No Intervention: positive symptoms<br> | |
| No Intervention: healthy control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET dopamine imaging and OGTT | PET dopamine imaging and OGTT after iTBS | immediate |
Evaluating Patients With Abnormal Levels of Gastric Acid

Study Overview
=================
Brief Summary
-----------------
This study is used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities in the secretion of gastric acid. The level of gastric acid is measured by analyzing the gastric juices of each individual patient. The gastric acid sample is obtained by a procedure known as nasogastric suctioning, where a thin plastic tube is passed from the nose to the stomach. Depending on the patient's present condition further diagnostic testing may be required to achieve a diagnosis.

Detailed Description
-----------------
This study is an omnibus protocol used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities of gastric acid secretion. Gastric acid secretion is measured by means of analysis of gastric juices obtained by nasogastric suction. Other clinically indicated diagnostic procedures are performed depending on the patient's clinical state in order to reach a diagnosis.

Official Title
-----------------
Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion

Conditions
-----------------
Achlorhydria, Gastrinoma, Zollinger Ellison Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Eligibility criteria not identified in the protocol.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stomach, Hypersecretion, Hyposecretion, Gastrinoma, Zollinger-Ellison Syndrome
Impact of Ophthalmic Surgeon Experience on Early Postoperative Central Corneal Thickness

Study Overview
=================
Brief Summary
-----------------
To assess the impact of surgeon experience on early postoperative central corneal thickness (CCT) in eyes that have undergone phacoemulsification-based cataract surgery.

Detailed Description
-----------------
Cataract surgery is the most commonly performed surgical procedure. Although phacoemulsification is considered a safe method of performing cataract surgery, the risk of endothelial cell loss (ECL) remains. Given that the surgical technique and speed typically improve with surgeon skill and experience, the purpose of this study was to evaluate the impact of surgeon experience on the occurrence of ECL, as reflected by the presence of corneal edema.

Official Title
-----------------
Impact of Ophthalmic Surgeon Experience on Early Postoperative Central Corneal Thickness After Cataract Surgery

Conditions
-----------------
Cataract

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of senile cataract Age above 50 years History of visual acuity regression Exclusion Criteria: Presence of white or Brown cataract History of previous ophtalmic surgery preexisting corneal pathology (cornea guttata, infectious keratitis or active inflammatory or old) Patients who developed intraoperative complications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early postoperative corneal edema | Calculated in micrometers, using pachymetric measurements to estimate central corneal thickness | hour 2 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Surgeon experience, Endothelial cell loss
Study Evaluating TMI-005 in Active Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
The primary objective of this clinical research study is to compare the efficacy and the safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active Rheumatoid Arthritis (RA) who have been receiving stable doses of Methotrexate (MTX).

Official Title
-----------------
A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: TMI-005


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet American College of Rheumatology (ACR) criteria for RA Have active RA Disease duration of at least 6 months Disease onset at > 16 years of age. Exclusion Criteria: Any prior use of anti-TNF alpha biologics, rituximab, receipt of anti-CD4 or diphtheria interleukin-2 fusion protein or other immunosuppressive biologics (except for anakinra) Largely or wholly incapacitated with the subject bedridden or confined to a wheelchair, permitting limited or no self-care Pregnant or breastfeeding women or women planning to become pregnant during the study or within 12 weeks after the last dose of test article

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: TMI-005|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
'Long COVID-19' in Suffolk and North Essex: Defining the Disease and Optimising Outcomes

Study Overview
=================
Brief Summary
-----------------
To accurately describe the rehabilitation needs of individuals with post-COVID-19 syndrome up to 36 months after infection, allowing better diagnosis, triage and resource management. A major focus will be the impact on everyday life to return to normal activities.

Official Title
-----------------
'Long COVID' in Suffolk and North Essex: Defining the Disease and Optimising Outcomes

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Individuals 18 years old and over (no upper age limit) Female and male Diagnosed with COVID-19 via PCR testing Or, Experienced symptoms of COVID-19 (new continuous cough, a high temperature, loss of taste and smell) And Clinically diagnosed with Post-COVID-19 Syndrome by their GP Participants who live within Suffolk and North East Essex Exclusion criteria Individuals unable to consent for themselves Individuals without sufficient proficiency in English language to take part in telephone or video call, where the research team have been unable to make adjustments to enable their participation Individuals under 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptomology | Wide range of symptoms associated with Long COVID | 36 months |
Taiwan Cancer Moonshot Project

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform.

Detailed Description
-----------------
Multiomic integrative analysis is an effective strategy to facilitate the investigation of molecular mechanism, cause, and early intervention of specific diseases. Gastric cancer is specifically chosen for our research target to decrease its incidence and improve survival. To increase precision diagnosis, prognosis and precision therapy, patients from Taiwan are selected as cohort subjects. The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform. Genome, transcriptome, genomic methylation, proteomics, and post-translational modification will be used to construct a map for determine the in-depth carcinogenesis of gastric cancer and strategies for cancer early diagnosis, prevention, and targeted treatments.

Official Title
-----------------
Taiwan Cancer Moonshot Project: 1. Next-generation Pathway of Taiwan Cancer Precision Medicine (Subjective Aim 1- Taiwan Cancer Moonshot Project); 2. Development of Novel Treatments for Major Diseases (Subproject 5 - Multiomic Big Data-based Intelligent Navigation System for Precision Oncology)

Conditions
-----------------
Malignant Neoplasm of Body of Stomach in Situ

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: lung cancer, breast cancer, gastric cancer, pancreatic cancer, ovarian cancer Exclusion Criteria: other cancer types

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data | Analyze collected clinical samples by using integrated proteomics and genetics platform (genome, transcriptome, genomic methylation, proteomics, and post-translational modification) | Through study completion, an average of 2 to 3 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differential expressed genes and proteins in tumor | The relative difference, or fold change of expressed genes and proteins (tumors vs adjacent normal tissue) | Through study completion, an average of 4 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung cancer, breast cancer, gastric cancer, pancreatic cancer, ovarian cancer
Antihypertensive Medications and the Risk of Sepsis

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study was to assess whether there is an increased risk of sepsis with the use of telmisartan compared with other ARBs and with the other major antihypertensive classes, including ACEIs, beta-blockers, CCBs and thiazide diuretics. A secondary objective was to assess whether the use of ARBs and ACEIs, compared with the other three major antihypertensive classes and with untreated hypertension, is associated with an increased risk of sepsis. A third objective was to evaluate whether the use of telmisartan compared with other ARBs, ACEIs and other major antihypertensive classes is associated with an increased risk of worse outcomes due to sepsis, in particular acute kidney injury and death

Official Title
-----------------
Antihypertensive Medications and the Risk of Sepsis

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Telmisartan
* Drug: Other angiotensin-receptor blockers (ARBs)
* Drug: Angiotensin-converting enzyme inhibitors (ACEIs)
* Drug: Other major antihypertensive medication classes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients, 18 years or older, with at least two-year follow-up in United Kingdom's general practice research database (GPRD), who had a diagnosis of or treatment for hypertension Exclusion Criteria: - Sepsis, chronic renal failure or on dialysis in the two-year period prior to cohort entry

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypertensive patients<br>Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data | Drug: Telmisartan<br> <br> Drug: Other angiotensin-receptor blockers (ARBs)<br> <br> Drug: Angiotensin-converting enzyme inhibitors (ACEIs)<br> <br> Drug: Other major antihypertensive medication classes<br>* e.g. beta-blockers, calcium channel blockers (CCBs), diuretics<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurence of sepsis, including severe sepsis | Severe sepsis defined as cases that develop renal failure or die within 30 days | Up to 9 years and 5 months |
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)

Official Title
-----------------
Long-Term Treatment, Multicenter, Open-Label Study With SPP100 in Patients With Essential Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: SPP100


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed as essential hypertension - Exclusion Criteria: Patients with secondary hypertension or suspected of having secondary hypertension. Patients suspected of having malignant hypertension Patients with any serious diseases or symptoms

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SPP100|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events, vital signs, abnormal laboratory changes,etc. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in diastolic blood pressure after 52 weeks |  |  | 
| Change from baseline in systolic blood pressure after 52 weeks |  |  | 
| Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 52 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, angiotensin, renin, aliskiren
Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
T1rho imaging is a new MRI technique that has strong potential in neuroimaging. This technique does not require exogenous contrast agents and has high spatial resolution. In this study we aim to characterise the normal appearance of T1rho in the brain parenchyma in healthy participants. T1rho values will be measured in normal brain structures.

Official Title
-----------------
Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects

Conditions
-----------------
Magnetic Resonance Imaging

Intervention / Treatment
-----------------
* Diagnostic Test: T1rho imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Male and female volunteers greater than or equal to 18 years of age Exclusion Criteria: Subjects with a contraindication to magnetic resonance imaging such as the presence of metallic implants, claustrophobia and pregnancy. Subjects with previous severe allergic or anaphylactoid reaction to a gadolinium contrast agent, or contraindication to contrast gadolinium administration, such severe renal disease or acutely deteriorating renal function, who would be at risk of nephrogenic systemic fibrosis Subjects who are unable to tolerate the scan without moving the head as a result of symptoms such as tremor, spasticity, involuntary movements and spasms, cognitive impairment, coughing, and shortness of breath.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: T1rho MRI<br> | Diagnostic Test: T1rho imaging<br>* Magnetic Resonance Imaging using T1rho<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| T1rho value in normal grey and white matter in healthy volunteers | T1rho value (measured on T1rho weighted MRI) in normal grey and white matter in healthy volunteers | Up to 2 months |
Pathophysiology Analysis of Costello Syndrome on Cellular Models

Study Overview
=================
Brief Summary
-----------------
The objective is to collect skin biopsies rom patients with Costello syndrome to analyze the molecular mechanisms responsible for this syndrome caused by a mutation in the HRAS gene and the effects of this mutation on energy metabolism and mitochondrial physiology.

Official Title
-----------------
Pathophysiology Analysis of Costello Syndrome on Cellular Models

Conditions
-----------------
Costello Syndrome

Intervention / Treatment
-----------------
* Procedure: Biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged over 2 years and under 18 Children with a Costello Syndrome or Syndrome Cardio-Facio-Cutaneous Exclusion Criteria: Previous history allergic to anesthetics

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Skin biopsy<br> | Procedure: Biopsy<br>* Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of HRASG12V mutation on mitochondrial energy metabolism |  | 1 day |